This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colleoni, M. Articles by Goldhirsch, A. Search for Related Content PubMed PubMed Citation Articles by Colleoni, M. Articles by Goldhirsch, A. Social Bookmarking                            What's this?

Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer

From the European Institute of Oncology, Milan; Oncologia Medica e Fondazione Beretta, Spedali Civili, Brescia, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute and Frontier Science and Technology Research Foundation, Boston, MA; Australian Cancer Society, and University of Sydney, Sydney; Anti-Cancer Council of Victoria, University of Melbourne, Melbourne, Australia; International Breast Cancer Study Group Coordinating Center, and Institute of Medical Oncology, Inselspital, Bern; Kantonsspital, St Gallen; Oncology Institute of Southern Switzerland, Ospedale Civico, Lugano, Switzerland; Western Swedish Breast Cancer Study Group, Sahlgrenska University Hospital, Göteborg, Sweden; Institute of Oncology, Ljubljana, Slovenia; Hospital de la Seguridad Social, Madrid, Spain; and Groote Schuure Hospital, Cape Town, South Africa.

Address reprint requests to Marco Colleoni, MD, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; email: marco.colleoni{at}ieo.it

PURPOSE: We investigated tumor- and patient-related features that might influence the response to perioperative chemotherapy (PeCT) compared with no adjuvant therapy for patients with node-negative breast cancer.

PATIENTS AND METHODS: A total of 1,275 patients were randomized to either no adjuvant treatment (427 patients) or PeCT (848 patients). The following variables thought to have prognostic significance were evaluated: grade, tumor size, estrogen (ER) and progesterone receptor (PgR) content (absent; low, 1 to 9 fmol/mg cytosol protein; or positive, 10 fmol/mg cytosol protein), c-erbB-2 overexpression, menopausal status, and age. Cox proportional hazards regression models were used to assess the relative influence of these factors to predict the effect of PeCT on disease-free survival (DFS). Median follow-up was 13.5 years.

RESULTS: The 10-year DFS percentage for 692 premenopausal patients did not significantly differ between the PeCT and no-adjuvant-treatment groups: 61% and 59%, respectively (relative risk [RR], 0.95; 95% confidence interval [CI], 0.75 to 1.20; P = .70). No predictive factors were identified. For 583 postmenopausal patients, 10-year DFS percentages for the groups were 63% and 58%, respectively (RR, 0.75; 95% CI, 0.58 to 0.93; P = .03). The absence of expression of ER, PgR, or both ER and PgR was the most important factor predicting improved outcome with PeCT among postmenopausal patients. The 10-year DFS percentages were 85% and 53% for the steroid hormone receptor–absent cohort of treated and untreated patients, respectively (RR, 0.18; 95% CI, 0.06 to 0.49; P = .0009).

CONCLUSION: The role of PeCT should be explored for patients whose primary tumors do not express steroid hormone receptors, because it is likely that early initiation of treatment is exclusively relevant for such patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann. Onc., July 1, 2009; 20(7): 1157 - 1162. [Abstract] [Full Text] [PDF]

				M. Colleoni, G. Viale, D. Zahrieh, L. Bottiglieri, R. D. Gelber, P. Veronesi, A. Balduzzi, R. Torrisi, A. Luini, M. Intra, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy Ann. Onc., March 1, 2008; 19(3): 465 - 472. [Abstract] [Full Text] [PDF]

				A Goldhirsch, A. Coates, R. Gelber, J. Glick, B Thurlimann, H-J Senn, and On behalf of the St Gallen Expert Panel Members First--select the target: better choice of adjuvant treatments for breast cancer patients Ann. Onc., December 1, 2006; 17(12): 1772 - 1776. [Abstract] [Full Text] [PDF]

				M. M. Regan, G. Viale, M. G. Mastropasqua, E. Maiorano, R. Golouh, A. Carbone, B. Brown, M. Suurkula, G. Langman, L. Mazzucchelli, et al. Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays. J Natl Cancer Inst, November 1, 2006; 98(21): 1571 - 1581. [Abstract] [Full Text] [PDF]

				M Colleoni, N Rotmensz, G Peruzzotti, P Maisonneuve, L Orlando, R Ghisini, G Viale, G Pruneri, P Veronesi, A Luini, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease Ann. Onc., October 1, 2006; 17(10): 1497 - 1503. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93 J. Clin. Oncol., March 20, 2006; 24(9): 1332 - 1341. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]

				M. Colleoni, S. Li, R. D. Gelber, A. S. Coates, M. Castiglione-Gertsch, K. N. Price, J. Lindtner, C.-M. Rudenstam, D. Crivellari, J. Collins, et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Ann. Onc., May 1, 2005; 16(5): 716 - 725. [Abstract] [Full Text] [PDF]

				M. Colleoni, G. Viale, D. Zahrieh, G. Pruneri, O. Gentilini, P. Veronesi, R. D. Gelber, G. Curigliano, R. Torrisi, A. Luini, et al. Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment Clin. Cancer Res., October 1, 2004; 10(19): 6622 - 6628. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial J Natl Cancer Inst, December 17, 2003; 95(24): 1833 - 1846. [Abstract] [Full Text] [PDF]

				H. Joensuu Primary chemotherapy of breast cancer followed by perioperative chemotherapy: feasible, but are there clinical benefits? Ann. Onc., October 1, 2003; 14(10): 1460 - 1462. [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365. [Abstract] [Full Text] [PDF]

				T. Petit, C. Borel, S. Theobald, D. Serin, J.-F. Rodier, G. Prevot, J.-P. Brettes, and T. Klein Randomized Multicentric Study of Perioperative Chemotherapy With Mitoxantrone in Early Breast Cancer Ann. Surg. Oncol., May 1, 2003; 10(4): 369 - 375. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group (IBCSG) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial J Natl Cancer Inst, July 17, 2002; 94(14): 1054 - 1065. [Abstract] [Full Text] [PDF]

				J. A. van der Hage, C. J.H. van de Velde, M. Colleoni, A. Goldhirsch, A. S. Coates, R. D. Gelber, S. Gelber, and M. Castiglione-Gertsch Perioperative Chemotherapy in Patients With Node-Negative Postmenopausal Breast Cancer J. Clin. Oncol., April 15, 2002; 20(8): 2210 - 2212. [Full Text] [PDF]